Core Viewpoint - The biopharmaceutical sector experienced a significant increase of 3.06% on September 5, with Sanofi leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% [1] - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Group 2: Individual Stock Performance - Sanofi (688336) closed at 61.60, with a rise of 11.80% and a trading volume of 165,400 shares, totaling a transaction value of 9.62 billion [1] - Changchun High-tech (000661) closed at 128.00, increasing by 7.53% with a trading volume of 270,100 shares [1] - Junshi Biosciences (688180) closed at 48.00, up 7.38% with a trading volume of 252,900 shares, totaling 1.17 billion [1] - Tibet Pharmaceutical (600211) closed at 50.48, rising by 7.13% with a trading volume of 220,200 shares, totaling 1.08 billion [1] - Other notable stocks include: - Rongan Bio (688331) at 92.17, up 4.32% [1] - Kexing Pharmaceutical (688136) at 42.27, up 4.14% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 231 million from institutional investors, while retail investors experienced a net outflow of 25.77 million [1]

中泰证券股份有限公司 关于北京诺思兰德生物技术股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件的规定，中泰证券股份有限公司（以下简称"中泰 证券"或"保荐机构"）作为北京诺思兰德生物技术股份有限公司（以下简称"诺 思兰德"或"公司"）的保荐机构，负责诺思兰德的持续督导工作，并出具 2025 年半年度持续督导跟踪报告。 | 项目 | 工作内容 | | --- | --- | | 1、审阅公司信息披露文件 | 保荐机构及时审阅公司信息披露文件。 | | 2、督导公司建立健全并有效 | 保荐机构督导公司建立健全规则制度（包括但不限于根据新 | | 执行规则制度 | 《公司法》及《上市规则》的规定，修改完善公司治理制度）， | | | 本督导期内，诺思兰德有效执行了规则制度。 | | 3、募集资金使用监督 | 保荐机构定期查阅公司募集资金账户对账单，核查公司募集 | | | 资金使用情况；前往公司现场核查募集资金使用情况。本督 | | | 导期内，诺思兰德募集资金存放与使用符合相关规定。 | | 4、督导公司规范运作 | ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

（文章来源：证券日报） 证券日报网讯 9月1日晚间，诺思兰德发布公告称，公司第六届监事会第十六次会议审议通过了《关于 取消监事会并修订〈公司章程〉的议案》等。 ...

Core Viewpoint - The company announced the approval of multiple resolutions, including the cancellation of the supervisory board and amendments to the company's articles of association during the 22nd meeting of the sixth board of directors [2] Group 1 - The company held its 22nd meeting of the sixth board of directors on September 1 [2] - The resolutions passed include the proposal to cancel the supervisory board [2] - Amendments to the company's articles of association were also approved [2]

Group 1 - The company, Norland, announced that it will hold its second extraordinary general meeting of shareholders on September 17, 2025 [1] - The agenda for the meeting includes the proposal to cancel the supervisory board and amend the company's articles of association [1]

Meeting and Attendance - The board meeting was convened and conducted in accordance with the Company Law and the Articles of Association, with valid voting results [1] - All 9 directors were present or authorized to attend, with some participating via communication means due to work commitments [1] Agenda Review - The proposal to abolish the supervisory board and amend the Articles of Association was approved, transferring the supervisory board's powers to the audit committee of the board [1] - The original rules governing the supervisory board were simultaneously abolished, and amendments to the Articles of Association were proposed for shareholder authorization [1] Internal Management System - A proposal to establish and amend certain internal management systems was approved, aimed at enhancing corporate governance and promoting standardized operations [2][4] - This proposal includes several sub-proposals related to various management systems, such as the rules for board meetings, shareholder meetings, and related party transaction management [2][4] Shareholder Meeting - The board proposed to convene the second extraordinary general meeting of shareholders in 2025 on September 17 to review related proposals [6] - This proposal does not involve related party transactions and does not require avoidance of voting [6]

Group 1 - The company has decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and will amend the relevant provisions in the Articles of Association accordingly [1][2] - The proposal to abolish the supervisory board and amend the Articles of Association has been approved by the supervisory board and will be submitted for shareholder meeting approval [2] - The proposal to abolish the "Rules of Procedure for the Supervisory Board of Beijing Northland Biotechnology Co., Ltd." has also been approved, as the supervisory board will no longer exist [2] Group 2 - The meeting was convened in accordance with the Company Law and the Articles of Association, with all voting results being legal and valid [1] - All three supervisors were present or authorized to attend the meeting, with one supervisor participating via telecommunication due to work commitments [1] - The proposals do not involve related party transactions and do not require abstention from voting [2]

证券代码：430047 证券简称：诺思兰德 公告编号：2025-066 北京诺思兰德生物技术股份有限公司独立董事工作制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.07： 《修订〈独立董事工作制 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为进一步完善北京诺思兰德生物技术股份有限公司（以下简称"公 司"）治理结构，充分发挥公司独立董事作用，促进公司规范运作，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《北京证券交易所上市公司持续监管办法（试行）》《上市公 司独立董事管理办法》、 ...

Core Viewpoint - The company has revised its profit distribution management system to enhance transparency and ensure sustainable development while protecting the rights of minority investors [1][2][3] Section Summaries 1. Review and Voting Situation - The company held its 22nd meeting of the 6th Board of Directors on September 1, 2025, where the proposal to revise the profit distribution management system was approved with 9 votes in favor, 0 against, and 0 abstentions [1] 2. General Principles - The revised system aims to standardize profit distribution practices, ensuring a scientific, sustainable, and stable distribution mechanism [3] - The company will strengthen its commitment to shareholder returns and adhere to legal regulations in profit distribution decisions [3] 3. Profit Distribution Order - The company will prioritize the rights of investors, especially minority shareholders, in its profit distribution policy [4] - Taxed profits will be allocated in a specific order, including mandatory allocations to statutory reserves and addressing previous losses before distributing profits to shareholders [4][5] 4. Profit Distribution Policy - The company will implement a stable profit distribution policy, considering factors such as profit, cash flow, and shareholder expectations [6] - Cash dividends will be prioritized when conditions are met, and the company will maintain a continuous and stable profit distribution policy [6][8] 5. Decision-Making Mechanism - The Board of Directors must conduct thorough research and discussions before proposing profit distribution plans, ensuring that minority shareholders' opinions are considered [9] - The audit committee will review the profit distribution proposals before they are submitted to the shareholders' meeting for approval [9] 6. Execution and Disclosure - The Board must complete the distribution of dividends within two months after the shareholders' meeting decision [10] - The company is required to disclose the profit distribution plan and its execution status in accordance with regulatory requirements [10][11]